Ab2 Bio
unknown
unknown
Stage
1
Investors
About
Develops antibody-drug conjugates (ADCs), i.e., engineered antibodies linked to cytotoxic payloads, intended as targeted therapeutics for oncology.
Explore Ab2 Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.